CHRIS J.J. MULDER; GUIDO N.J. TYTGAT; WILLEM DEKKER; IDO J. TERPSTRA
This content is PDF only. Please click on the PDF icon to access.
To the editor: 5-Aminosalicylic acid (5-ASA) is the effective moiety of sulfasalazine. The sulfapyridine moiety is usually considered to be the cause of intolerance in most of the patients who have side-effects from sulfasalazine therapy (1). Slow-release 5-ASA products have been developed, therefore, to bypass these problems. Pentasa (Gist-Brocades, the Netherlands) consists of 5-ASA microencapsulated in ethyl cellulose. Release of 5-ASA increases as the product travels down the intestine into a median with rising pH (2). We studied whether patients intolerant to sulfasalazine could tolerate Pentasa.
Seventy-one patients, aged 18 to 75 years, were entered into the study. The reasons
MULDER CJ, TYTGAT GN, DEKKER W, et al. Pentasa in Lieu of Sulfasalazine. Ann Intern Med. 1988;108:911–912. doi: 10.7326/0003-4819-108-6-911_2
Download citation file:
Published: Ann Intern Med. 1988;108(6):911-912.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use